-- CFO with Proven Track Record in the Biopharmaceutical Industry --
NEW HAVEN, Conn.--(BUSINESS WIRE)--
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Paul J.
Clancy, a seasoned financial executive with 30 years of experience, will
join the company on July 10, 2017 and will assume the role of Chief
Financial Officer (CFO) effective July 31, 2017. For the past 16 years,
Mr. Clancy has been employed by Biogen where he has served as CFO for
the last ten years. Prior to Biogen, Mr. Clancy spent 13 years with
PepsiCo in various executive positions. Mr. Clancy will succeed Dave
Anderson, who will continue to serve as CFO until July 31, 2017. To
ensure a smooth transition, Mr. Anderson will then become a Senior
Advisor to the Chief Executive Officer and will remain with Alexion
until the end of August.
"I couldn't be more pleased to welcome Paul to Alexion," said Ludwig
Hantson, Chief Executive Officer of Alexion. "Paul is a world-class CFO
who has distinguished himself in the biopharmaceutical industry. He
brings deep experience and a proven track record of managing a global
organization, executing successful financial and capital allocation
strategies to deliver long-term shareholder value, and cultivating
strong relationships with the investment community. He is an outstanding
addition to our team and we look forward to his leadership, insights and
partnership as we position Alexion for its next stage of growth."
"I've worked in the biopharmaceutical industry for many years, and I
have been consistently impressed with Alexion and the life-changing
therapies the company has brought to patients with rare diseases," said
Mr. Clancy. "I'm very excited to join Alexion and look forward to
working with the leadership team and leading the finance organization to
build upon the company's strong fundamentals and drive future growth and
Dr. Hantson added, "Dave Anderson will work closely with Paul to ensure
a smooth and seamless transition. We appreciate the valuable
contributions that Dave has made during his tenure. We wish Dave all the
best in his future endeavors."
Brief Biography for Paul Clancy
Mr. Clancy most recently served as the Executive Vice President, Finance
and Chief Financial Officer and a member of the Executive Committee of
Biogen, where he led the financial performance of the company,
delivering 16% average annual revenue growth and 25% average annual
non-GAAP EPS growth over the past ten years. He joined Biogen in 2001
and was named Chief Financial Officer in 2007, having served in several
other senior executive positions with the company, including Senior Vice
President of Finance, Vice President of Business Planning, Vice
President of Portfolio Management, and Vice President of U.S. Marketing.
Prior to that, he spent 13 years at PepsiCo, serving in a range of
finance, strategy and general management positions. Mr. Clancy serves on
the Board of Directors of Agios Pharmaceuticals, Inc., a
biopharmaceutical company and on the Board of Directors of Incyte
Corporation, also a biopharmaceutical company. Mr. Clancy received his
B.S. in Finance from Babson College and M.B.A. from Columbia University.
Alexion is a global biopharmaceutical company focused on developing and
delivering life-transforming therapies for patients with devastating and
rare disorders. Alexion is the global leader in complement inhibition
and has developed and commercializes the first and only approved
complement inhibitor to treat patients with paroxysmal nocturnal
hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two
life-threatening ultra-rare disorders. In addition, Alexion's metabolic
franchise includes two highly innovative enzyme replacement therapies
for patients with life-threatening and ultra-rare disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
Alexion is advancing its rare disease pipeline with highly innovative
product candidates in multiple therapeutic areas. This press release and
further information about Alexion can be found at: www.alexion.com.
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended. These
forward-looking statements often include words such as "anticipate,"
"believe," "expect," "will," or similar expressions. Forward-looking
statements are subject to factors that may cause Alexion's results and
plans to differ from those expected, including for example, risks
related to potential disruptions to our business as a result of
leadership changes, and a variety of other risks set forth from time to
time in Alexion's filings with the U.S. Securities and Exchange
Commission, including but not limited to the risks discussed in
Alexion's Quarterly Report on Form 10-Q for the period ended March 31,
2017 and in our other filings with the U.S. Securities and Exchange
Commission. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the
date hereof, except when a duty arises under law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170613005908/en/
Executive Director, Corporate Communications
Ridloff, CFA, 475-230-3601
Vice President, Investor Relations
Director, Investor Relations
Source: Alexion Pharmaceuticals Inc.
News Provided by Acquire Media